Smith & Nephew stock gains after Jefferies restates buy

Smith & Nephew stock trades at GBX 1,052 after Jefferies restated its buy call and set a GBX 1,500 target. MarketBeat also showed a consensus target of GBX 1,310 on September 4, 2026.

Smith & Nephew plc (GB0009223206) stock traded at GBX 1,052 on September 4, 2026, after Jefferies Financial Group restated its buy rating and set a GBX 1,500 target price. MarketBeat said that target implies 42.59 percent upside from the previous close.

Analysts lift the tone

MarketBeat also reported a consensus rating of Hold and a consensus target price of GBX 1,310 on September 4, 2026. Shares opened at GBX 1,052, which leaves the stock 24.2 percent below that consensus target.

Price versus valuation

The same source put the market cap at GBP 11.53 billion, the 50-day moving average at GBX 1,118.14, and the 200-day moving average at GBX 1,169.82. On that basis, the stock sat below both trend lines, while the Jefferies target stood 42.59 percent above the previous close.

Orthopedics still matters

Smith & Nephew operates through Orthopaedics, Sports Medicine & ENT and Advanced Wound Management, according to the MarketBeat company profile. That mix matters because valuation is being judged against a business that still leans on implants, trauma and wound care rather than a single product cycle.

Stock at a glance

At the close on September 3, 2026, Yahoo Finance showed SNN at USD 28.69, after a pre-market quote of USD 28.86 on September 4, 2026. The same page showed a YTD return of -11.96 percent, compared with +9.09 percent for the FTSE 100, and a dividend of USD 0.312 with an ex-date of October 2, 2026.

Smith & Nephew stock facts

• Company: Smith & Nephew plc
• ISIN: GB0009223206
• Ticker: SN
• Trading venue: London Stock Exchange
• Price (as of September 3, 2026): GBX 1,052
• Market capitalization: GBP 11.53 billion
• Sector / Industry: Health Care / Medical Devices
• Index membership: FTSE 100